Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France; International associated laboratory (LIA) CNRS 'IM-TB/HIV', Toulouse, France
Shanti Souriant
Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France; International associated laboratory (LIA) CNRS 'IM-TB/HIV', Toulouse, France
Luciana Balboa
International associated laboratory (LIA) CNRS 'IM-TB/HIV', Toulouse, France; Institute of Experimental Medicine-CONICET, National Academy of Medicine, Buenos Aires, Argentina
Thien-Phong Vu Manh
Aix Marseille Univ, CNRS, INSERM, CIML, Marseille, France
Karine Pingris
Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France
Stella Rousset
Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France
Céline Cougoule
Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France; International associated laboratory (LIA) CNRS 'IM-TB/HIV', Toulouse, France
Yoann Rombouts
Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France
Renaud Poincloux
Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France
Myriam Ben Neji
Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France
Carolina Allers
Tulane National Primate Research Center, Department of Microbiology and Immunology, School of Medicine, Tulane University, Covington, United States
Deepak Kaushal
Tulane National Primate Research Center, Department of Microbiology and Immunology, School of Medicine, Tulane University, Covington, United States
Marcelo J Kuroda
Tulane National Primate Research Center, Department of Microbiology and Immunology, School of Medicine, Tulane University, Covington, United States
Susana Benet
IrsiCaixa AIDS Research Institute, Department of Retrovirology, Badalona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain
Javier Martinez-Picado
IrsiCaixa AIDS Research Institute, Department of Retrovirology, Badalona, Spain; University of Vic-Central University of Catalonia (UVic-UCC), Vic, Spain; Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain
Nuria Izquierdo-Useros
IrsiCaixa AIDS Research Institute, Department of Retrovirology, Badalona, Spain; Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain
Maria del Carmen Sasiain
International associated laboratory (LIA) CNRS 'IM-TB/HIV', Toulouse, France; Institute of Experimental Medicine-CONICET, National Academy of Medicine, Buenos Aires, Argentina
Isabelle Maridonneau-Parini
Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France; International associated laboratory (LIA) CNRS 'IM-TB/HIV', Toulouse, France
Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France; International associated laboratory (LIA) CNRS 'IM-TB/HIV', Toulouse, France
Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France; International associated laboratory (LIA) CNRS 'IM-TB/HIV', Toulouse, France
Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, Toulouse, France; International associated laboratory (LIA) CNRS 'IM-TB/HIV', Toulouse, France
While tuberculosis (TB) is a risk factor in HIV-1-infected individuals, the mechanisms by which Mycobacterium tuberculosis (Mtb) worsens HIV-1 pathogenesis remain scarce. We showed that HIV-1 infection is exacerbated in macrophages exposed to TB-associated microenvironments due to tunneling nanotube (TNT) formation. To identify molecular factors associated with TNT function, we performed a transcriptomic analysis in these macrophages, and revealed the up-regulation of Siglec-1 receptor. Siglec-1 expression depends on Mtb-induced production of type I interferon (IFN-I). In co-infected non-human primates, Siglec-1 is highly expressed by alveolar macrophages, whose abundance correlates with pathology and activation of IFN-I/STAT1 pathway. Siglec-1 localizes mainly on microtubule-containing TNT that are long and carry HIV-1 cargo. Siglec-1 depletion decreases TNT length, diminishes HIV-1 capture and cell-to-cell transfer, and abrogates the exacerbation of HIV-1 infection induced by Mtb. Altogether, we uncover a deleterious role for Siglec-1 in TB-HIV-1 co-infection and open new avenues to understand TNT biology.